Dexcom Inc (DXCM) is overvalued and Stryker Corp (SYK) is overvalued.
Both trade above our estimate of their intrinsic value. SYK is the closer of the two: -35%, against -61% for DXCM.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 11.4% (average of 3 methods) values the shares at $55.75; the price of $89.53 is 61% above that value, and 70% of that value comes from beyond year five.
Leak Score 68/100 on 9 of 12 signals
Discounting its cash flows at 8.7% (average of 3 methods) values the shares at $204.41; the price of $275.09 is 35% above that value, and 77% of that value comes from beyond year five.
Leak Score 65/100 on 10 of 12 signals
| Metric | DXCM | SYK |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $89.53 | $275.09 |
| Intrinsic value | $55.75 | $204.41 |
| Margin of safety | -61% | -35% |
| Leak Score | 68/100 (9/12) | 65/100 (10/12) |
| Market cap | $33.8B | $105.5B |
| Revenue growth, 5 years | 19.3% | 11.8% |
| Operating margin | 22.9% | 24.3% |
| Net margin | 20.1% | 14.4% |
| Return on equity | 38.5% | 16.5% |
| Debt to equity | 0.53 | 0.64 |
| P/E | 35.3x | 28.5x |
| Forward P/E | 28.7x | 16.4x |
| P/B | 12.9x | 4.4x |
| Dividend yield | — | 1.3% |